Eli Lilly and Company’s (LLY) Overweight Rating Reaffirmed at Cantor Fitzgerald

Eli Lilly and Company (NYSE:LLY)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports. They currently have a $885.00 target price on the stock. Cantor Fitzgerald’s price objective would suggest a potential downside of 0.22% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the stock. Truist Financial lifted their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Bank of America lifted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $803.50.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $3.09 during trading on Monday, hitting $886.97. 391,293 shares of the stock traded hands, compared to its average volume of 2,927,704. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company has a market cap of $842.99 billion, a price-to-earnings ratio of 130.63, a P/E/G ratio of 1.93 and a beta of 0.36. The company has a fifty day moving average price of $798.59 and a two-hundred day moving average price of $729.89. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $905.45.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the company earned $1.62 EPS. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, equities analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 772,475 shares of company stock worth $656,838,859. Company insiders own 0.13% of the company’s stock.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently made changes to their positions in LLY. Milestone Asset Management LLC boosted its holdings in Eli Lilly and Company by 4.1% in the third quarter. Milestone Asset Management LLC now owns 759 shares of the company’s stock valued at $409,000 after purchasing an additional 30 shares in the last quarter. Mckinley Capital Management LLC boosted its holdings in Eli Lilly and Company by 51.3% in the third quarter. Mckinley Capital Management LLC now owns 7,675 shares of the company’s stock valued at $4,123,000 after purchasing an additional 2,602 shares in the last quarter. Winslow Capital Management LLC boosted its holdings in Eli Lilly and Company by 33.3% in the third quarter. Winslow Capital Management LLC now owns 646,877 shares of the company’s stock valued at $347,457,000 after purchasing an additional 161,509 shares in the last quarter. Truvestments Capital LLC boosted its holdings in Eli Lilly and Company by 13.9% in the third quarter. Truvestments Capital LLC now owns 410 shares of the company’s stock valued at $220,000 after purchasing an additional 50 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $3,874,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.